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CASE REPORT
Complement deficiencies are rare inherited dis-
orders. Data on their overall prevalence indicate
that they occur in about 0.03% of the general
population.1 Deficiencies of the early components
of complement, C1, C2 or C4, are frequently asso-
ciated with autoimmune diseases such as systemic
lupus erythematosus or dermatomyositis. Late
component deficiencies, on the other hand, are
associated with infections caused by encapsu-
lated organisms. The late complement system
consists of components C5–C9, which are in-
volved in the membrane-attack complex. This
complex forms transmembrane channels that
lead to cell lysis and death.2 The association 
between inherited deficiencies of terminal com-
plement components and increased suscepti-
bility to Neisseria meningitidis infection is well
established.3,4 In this article, we report a Taiwanese
patient with a deficiency of C7.
Case Report
A 5-year-4-month-old boy was healthy until
March 2000 when he developed fever (tempera-
ture, 39–40°C) and chills, followed by headache,
vomiting and fgeneral weakness. After 2 days o
fever, he was taken to another hospital, where urine
and stool incontinence and decreased level of con-
ysciousness were found. He was treated empiricall
with amoxicillin and cefotaxime after blood was
taken for culture. He became hypotensive and was
given a saline challenge, after which he was trans-
ferred to our hospital. His past medical history was 
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unremarkable. His growth and development had
been normal, and he had no other serious ill-
nesses or hospitalizations. There was no family
history of immunodeficiency, meningitis or other
inflammatory or inherited diseases.
On admission, the patient appeared ill, and
was drowsy and delirious. His temperature was
39.1°C, heart rate was 110/minute and blood pres-
sure was 110/74 mmHg. He had photophobia.
Neurologic examination showed nuchal rigidity
with Brudzinski’s sign. His lungs were clear; aus-
cultation of the heart revealed tachycardia without
murmur. Abdominal examination was normal.
There were erythematous maculopapules and pur-
pura scattered over the face, neck, trunk and limbs.
Hemogram showed a white blood cell count 
of 20,060/mm3 with 46% segmented forms, 44%
bands and 6% lymphocytes. Hemoglobin was 
10.5 g/dL and platelet count was 76,000/mm3.
C-reactive protein was elevated to 22.5 mg/dL.
Activated partial thromboplastin time was 53.6
seconds (control, 28.9 seconds), prothrombin time
was 15.1 seconds (control, 11.2 seconds) and fibrin
degradation products were > 32 μg/mL (normal,
<5 μg/mL), consistent with disseminated intravas-
cular coagulation. Lumbar puncture yielded cloudy
cerebrospinal fluid (CSF) with an opening pres-
sure of 123 mmH2O, a protein level of 341 mg/dL
(normal, 10–45 mg/dL), a glucose level of 0 mg/dL
(normal, 45–75 mg/dL), a red blood cell count of
540/mL and a white blood cell count of 4896/mL
(96% neutrophils). Gram stain of a CSF smear
showed multiple polymorphonuclear cells with
intracellular Gram-negative diplococci. Meningo-
coccal meningitis was suspected, and the patient
was treated with penicillin G 500,000 U/kg/day
and cefotaxime 200 mg/kg/day. Urine and CSF
agglutination tests were positive for N. meningi-
tidis. Blood cultures from the first hospital grew 
N. meningitidis, which the laboratory at the
Taiwan Center for Disease Control demonstrated
to be serotype W-135. Cultures from CSF, blood
and urine done in our hospital were negative for
aerobic and anaerobic bacteria. The patient’s
fever resolved on the 10th day of hospitalization,
and after the completion of a 2-week course of
antibiotics, he was discharged in stable condi-
tion. All persons who had had close contact with
the patient received chemoprophylaxis with 
rifampin (600 mg every 12 hours for 2 days).
Immunologic studies were performed 15 days
after discharge. The CH50 level was undetectable
at < f6 U/mL (normal, 32.6–39.8 U/mL). Levels o
C3, C4, C5, C6 and C8 were normal, but C7 was
undetectable (< 5.8 mg/dL; reference, 55–85 mg/
dL). Serum levels of complement were measured
by single radial immunodiffusion method (Bind-
ing Site, Birmingham, UK). Levels of IgG, IgA, IgM
and IgE were all within normal limits; CD3 was
54.2%, CD4 was 20.6%, CD8 was 25.2%, CD19
was 13.6%, CD57 was 27.9% and active T cells
gwere 19.7% (reference, 8–15%). Neutrophil killin
of bacteria at 30 minutes was 31.1% (control,
35.1%), at 1 hour was 45.1% (control, 48.6%) and
at 2 hours was 54.4% (control, 63.2%). Neu-
trophil chemotaxis was 2.1 (reference, > 1.2) and
delayed cutaneous hypersensitivity tests (Multi-
rtest CMI, Pasteur Merieux, Lyons, France) fo
tetanus toxoid, diphtheria toxoid, streptococcus
group C antigen, tuberculin, Candida albicans and
Proteus mirabilis ywere all positive. C7 deficienc
was diagnosed and the patient was given tetrava-
lent meningococcal vaccine for prophylaxis. The
patient’s complement immunity was rechecked
on April 2003, and the CH50 level and serum
rC7 remained undetectable. He had no furthe
episodes of meningitis over the following 5 years.
His family members were also screened for com-
plement deficiencies (Table), revealing that his
sister was also C7 deficient (CH50 < 6 U/mL, C7 
< 5.8 mg/dL). His father’s CH50 Lwas 25.9 U/m
and C7 was 27.8 mg/dL. His mother’s CH50 was
31.2 U/mL and C7 was 22.7 mg/dL. Both parents
thus had partial C7 deficiency, consistent with
autosomal codominant inheritance of a com-
plete deficiency in the children.
Discussion
After Boyer et al5 first described C7 deficiency in
1975, cases have been reported in different parts
f fC7 de iciency and meningococcal in ection
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of the world and in different ethnic groups.4,6–9
However, C7 deficiency has not previously been
reported in Taiwan. Individuals with homozy-
gous C7 deficiency have almost complete ab-
sence of detectable C7, leading to an inability to
generate the membrane attack complex and a
lack of serum hemolytic and bactericidal activ-
ity.3 The combined action of antibodies against
meningococcus and complement is essential for
a serum bactericidal effect2 and prevention of
systemic meningococcal disease.10
Genetically determined human deficiencies of
any of the terminal complement components are
associated with increased susceptibility to N.
meningitidis infections,4,11,12 with a risk of meningo-
coccal disease estimated to be 10,000 times greater
than normal.13 Approximately 80% of all systemic
bacterial infections identified in complement defi-
cient individuals are caused by meningococcus.13
Comparison of the clinical features of meningo-
coccal disease in complement-sufficient and
-deficient individuals shows interesting differ-
ences in the median age at first infection, in the
frequency of recurrence and relapses, and in mor-
tality.4 While the average age at the onset of the first
meningococcal infection is 3 years in the general
population, it is 17 years in complement-deficient
patients.14 Previous infection with meningococcus
in patients with deficiency of the late components
of complement does not reduce the risk of new
episodes; relapses and recurrent disease (new infec-
tion more than 1 month after a previous episode)
occur 10 and 150 times more frequently than 
in the general population, respectively. However,
mortality from meningococcal disease is 5- to
10-fold lower in patients with complement defi-
ciency as compared to the general population.13
The most common meningococcal serotype
in healthy individuals is group B, while unusual
meningococcal serotypes (particularly Y, W-135
and X) are the ones that usually infect patients
with complement deficiencies.4,13,15 fIn a study o
7732 patients with meningococcal disease in the
Netherlands, the prevalence of complement defi-
ciency was 3%, but among patients with unusual
serotypes, the prevalence of any complement defi-
ciency was 33%.16 Complement deficiency should
therefore be suspected in a patient infected with an
uncommon meningococcal serotype. From 1995
to 2002, there were 159 cases of N. meningitidis
yinfection reported in Taiwan. Serotype stud
showed that 86 (54.09%) infections were group
B, 46 (28.93%) were group W-135, 18 (11.32%)
were group C, 15 (9.43%) were group Y and 6
(3.77%) were group A. Our patient was infected
with serotype W-135. The serotype was not un-
usual in Taiwan. Complement deficiency is rare
in Taiwan, and our review of the literature found
no previous reports of a late complement defi-
ciency. Further study of the difference between
immune sufficient and immunodeficient sub-
jects with N. meningitidis in Taiwan is required.
The total hemolytic complement (CH50 t) tes
tmeasures the function of the classic complemen
cascade.17 Absent or decreased CH50 timplies tha
at least one of the necessary components is miss-
ing or low.18 To confirm the specific defect, an im-
munochemical method is used to quantitate the
individual components.17 C7 was undetectable
rin our patient’s serum by either functional o
Table. Results of complement studies performed in the proband and his family
Complement hemolytic Complement concentration,mg/dL
activity (CH50) C3 C4 C5 C6 C7 C8
Patient < 6.3 179 23 224 118 < 5.85 194
Sister < 6.3 116 26.7 120 92 < 5.85 163
Father 25.9 82 16 101 59 27.8 109
Mother 31.2 83.1 14.4 110 86 22.7 109
Normal 32.6–39.8 77–195 7–40 90–172 45–96 55–85 112–172
range
immunochemical analysis. The levels of the other
components were within the normal range, con-
firming the diagnosis of C7 deficiency.
The gene for C7 spans about 80 kb of DNA, is
encoded by 18 exons, and is located on chromo-
some 5p13. To date, more than 15 different molec-
ular defects leading to C7 deficiency have been
reported.7 All previously reported cases of C7 defi-
ciency have followed an autosomal codominant in-
heritance pattern,6,19,20 the same as in our patient’s
family. Both the patient and his younger sister were
homozygous for complete C7 deficiency, while the
parents were heterozygous and had partial C7 defi-
ciency. Heterozygosity results in reduced C7 levels,
but sufficient complement activity remains to pre-
vent overt clinical manifestations of the deficiency.3
Prevention of further attacks is integral to the
long-term management of complement-deficient
patients.11 Patients and their family should be
educated to recognize the early manifestations of
meningococcal infection. The Centers for Disease
Control in the United States recommend group
A, C, Y and W-135 tetravalent meningococcal
vaccine for complement-deficient individuals.21
On May 2000, our patient was given the tetravalent
meningococcal vaccine for prevention of further
attack. Replacement therapy with C7, although
theoretically capable of completely correcting the
immune defect, is not clinically feasible. When
the component is given to a C7-deficient person,
it has a half-life of only 91 hours.5 In addition,
regular transfusion of complement components
may generate antibodies, which would render the
treatment ineffective in the long term.3,22 Another
approach to prevent recurrent meningococcal
infection is the administration of prophylactic
penicillin. While this is effective in areas highly
endemic for meningococcal infection, it has not
been as successful in non-endemic areas. However,
complement-deficient individuals who may tem-
porarily be at increased risk, for example, during
foreign travel or local outbreaks, may be given pro-
phylactic penicillin.11
In conclusion, this case illustrates that, al-
though previously unreported, deficiency of a late
component of complement does exist in the gene
pool in Taiwan. This disorder should be included
in the differential diagnosis of patients with re-
current or invasive meningococcal disease and in
those who are infected with uncommon meningo-
coccal serotypes.
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